Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

IPSC

Century Therapeutics (IPSC)

Century Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPSC
DateTimeSourceHeadlineSymbolCompany
07/05/202406:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IPSCCentury Therapeutics Inc
23/04/202421:00GlobeNewswire Inc.Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:IPSCCentury Therapeutics Inc
11/04/202421:00GlobeNewswire Inc.Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsNASDAQ:IPSCCentury Therapeutics Inc
09/04/202406:05GlobeNewswire Inc.Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IPSCCentury Therapeutics Inc
25/03/202422:00GlobeNewswire Inc.Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsNASDAQ:IPSCCentury Therapeutics Inc
19/03/202422:00GlobeNewswire Inc.Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:IPSCCentury Therapeutics Inc
14/03/202422:30GlobeNewswire Inc.Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:IPSCCentury Therapeutics Inc
09/03/202410:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IPSCCentury Therapeutics Inc
08/03/202408:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IPSCCentury Therapeutics Inc
07/03/202408:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IPSCCentury Therapeutics Inc
06/03/202410:03GlobeNewswire Inc.Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:IPSCCentury Therapeutics Inc
22/02/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IPSCCentury Therapeutics Inc
22/02/202405:04Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IPSCCentury Therapeutics Inc
17/02/202408:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IPSCCentury Therapeutics Inc
08/02/202409:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IPSCCentury Therapeutics Inc
08/02/202409:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IPSCCentury Therapeutics Inc
07/02/202408:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IPSCCentury Therapeutics Inc
06/02/202407:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IPSCCentury Therapeutics Inc
01/02/202423:00GlobeNewswire Inc.Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:IPSCCentury Therapeutics Inc
20/01/202409:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IPSCCentury Therapeutics Inc
12/12/202302:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IPSCCentury Therapeutics Inc
10/12/202304:00GlobeNewswire Inc.Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ EditsNASDAQ:IPSCCentury Therapeutics Inc
07/12/202308:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IPSCCentury Therapeutics Inc
07/12/202308:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IPSCCentury Therapeutics Inc
06/12/202323:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IPSCCentury Therapeutics Inc
06/12/202323:30GlobeNewswire Inc.Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusNASDAQ:IPSCCentury Therapeutics Inc
06/12/202323:30GlobeNewswire Inc.Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus ErythematosusNASDAQ:IPSCCentury Therapeutics Inc
21/11/202323:00GlobeNewswire Inc.Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:IPSCCentury Therapeutics Inc
09/11/202323:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IPSCCentury Therapeutics Inc
09/11/202323:01GlobeNewswire Inc.Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IPSCCentury Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IPSC